A Phase I Safety and Bioimaging Trial of DS-8895a in Patients With Advanced or Metastatic EphA2 Positive Cancers
Phase of Trial: Phase I
Latest Information Update: 05 Mar 2019
Price : $35 *
At a glance
- Drugs DS 8895 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 04 Oct 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.
- 04 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.